The estimated Net Worth of John M Sprague is at least $324 dollars as of 24 February 2024. Mr. Sprague owns over 29 units of T2 Biosystems Inc stock worth over $324 and over the last 7 years he sold TTOO stock worth over $0. In addition, he makes $0 as Chief Financial Officer at T2 Biosystems Inc.
John has made over 9 trades of the T2 Biosystems Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 29 units of TTOO stock worth $67 on 24 February 2024.
The largest trade he's ever made was exercising 145,719 units of T2 Biosystems Inc stock on 24 February 2022 worth over $335,154. On average, John trades about 14,000 units every 138 days since 2018. As of 24 February 2024 he still owns at least 141 units of T2 Biosystems Inc stock.
You can see the complete history of Mr. Sprague stock trades at the bottom of the page.
John M. Sprague serves as Chief Financial Officer of the Company. He has served as our Chief Financial Officer since January 2018. Prior to joining our company, Mr. Sprague was Chief Financial Officer at Caliber Imaging & Diagnostics, Inc., a medical technologies company that designs, develops and markets innovative digital imaging solutions that show tissue at the cellular level using in-vivo confocal microscopes designed specifically for imaging skin and other tissues for pathology and life sciences, from February 2017 to January 2018. From 2011 to 2017, Mr. Sprague held various positions at GE Healthcare, with his last assignment serving as Finance Manager of GE’s North American Core Imaging business. Mr. Sprague is a certified public accountant and received his BS in accounting from Boston College.
John Sprague is 61, he's been the Chief Financial Officer of T2 Biosystems Inc since 2018. There are 5 older and 13 younger executives at T2 Biosystems Inc. The oldest executive at T2 Biosystems Inc is John Cumming, 74, who is the Lead Independent Director.
John's mailing address filed with the SEC is 101, Hartwell Avenue, Lexington, Middlesex County, Massachusetts, 02421, United States.
Over the last 10 years, insiders at T2 Biosystems Inc have traded over $18,971,153 worth of T2 Biosystems Inc stock and bought 5,875,341 units worth $59,722,018 . The most active insiders traders include Adrian M Jones, Group L.P.Crg Partners Iii ... und Thomas J. Carella. On average, T2 Biosystems Inc executives and independent directors trade stock every 20 days with the average trade being worth of $764,499. The most recent stock trade was executed by John J Iii Sperzel on 24 February 2024, trading 67 units of TTOO stock currently worth $154.
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www
T2 Biosystems Inc executives and other stock owners filed with the SEC include: